GLAXOSMITHKLINE PLC's ticker is GSK and the CUSIP is 37733W105. A total of 827 filers reported holding GLAXOSMITHKLINE PLC in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,186,000 | +59.9% | 252,420 | +57.2% | 4.47% | +18.5% |
| Q1 2022 | $6,994,000 | +39.3% | 160,568 | +41.0% | 3.77% | +0.7% |
| Q4 2021 | $5,021,000 | +40.6% | 113,866 | +21.8% | 3.75% | +14.5% |
| Q3 2021 | $3,572,000 | +2.3% | 93,485 | +6.6% | 3.27% | +0.2% |
| Q2 2021 | $3,492,000 | +18.2% | 87,686 | +5.9% | 3.27% | +6.4% |
| Q1 2021 | $2,955,000 | -63.1% | 82,792 | -62.0% | 3.07% | -2.1% |
| Q4 2020 | $8,016,000 | +20.9% | 217,817 | +23.6% | 3.14% | -2.2% |
| Q3 2020 | $6,632,000 | +26.4% | 176,186 | +36.9% | 3.21% | +18.5% |
| Q2 2020 | $5,248,000 | +8.1% | 128,664 | +0.4% | 2.71% | -13.3% |
| Q1 2020 | $4,854,000 | -19.7% | 128,112 | -0.5% | 3.13% | +13.0% |
| Q4 2019 | $6,047,000 | +9.5% | 128,695 | -0.5% | 2.77% | +3.9% |
| Q3 2019 | $5,521,000 | +7.0% | 129,352 | +0.3% | 2.66% | +7.0% |
| Q2 2019 | $5,159,000 | – | 128,907 | – | 2.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Healthcare Value Capital, LLC | 100,000 | $3,680,000 | 12.40% |
| Black Creek Investment Management Inc. | 7,443,061 | $273,905,000 | 8.54% |
| KAHN BROTHERS GROUP INC | 1,281,924 | $47,174,803,000 | 8.23% |
| Camber Capital Management LP | 3,500,000 | $128,800,000 | 4.52% |
| Eversept Partners, LP | 946,581 | $35,196,522 | 4.13% |
| EQUITY INVESTMENT CORP | 2,321,164 | $85,419,000 | 3.98% |
| Galibier Capital Management Ltd. | 575,741 | $21,187,000 | 3.66% |
| Keystone Financial Planning, Inc. | 217,399 | $8,000,000 | 3.32% |
| CLIFFORD CAPITAL PARTNERS LLC | 217,817 | $8,016,000 | 3.14% |
| CLARK ESTATES INC/NY | 485,000 | $17,848,000 | 2.52% |